1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Rapid advances in genotyping and next generation sequencing technologies have led to the identification of genetic variants that are associated with a wide variety of congenital defects including human congenital anomalies (HCAs), intellectual developmental disabilities (IDDs) and inborn errors of metabolism (IEMs). Large quantities of genomic data collected from pediatric congenital anomalies cohorts are available to the research community through several databases such as the Database of Genotypes and Phenotypes (dbGaP), the Gabriella Miller Kids First Data Resource Portal, the European Genome-Phenome Archive and Clinical Genome Resource (ClinGen). The purpose of this initiative is to promote the screening, functional validation and characterization of congenital anomaly-associated genetic variants identified through public facing databases and individual efforts using in-silico tools, appropriate animal models, in vitro systems or multi-pronged approaches. This initiative addresses a challenging gap between identifying sequence variations of potential interest and recognizing which of those variations have functional effects on the phenotype of interest.
Funding Opportunity Number: PAR-25-185. Assistance Listing: 93.121,93.351,93.865. Funding Instrument: G. Category: HL,ISS.
Get alerted about grants like this
Get emailed when new opportunities from “National Institutes of Health” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Eligible applicants: State governments; County governments; City or township governments; Special district governments; Independent school districts; Public and State controlled institutions of higher education; Native American tribal governments (Federally recognized); Public housing authorities / Indian housing authorities; Native American tribal organizations (other than Federally recognized); Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; For-profit organizations other than small businesses; Small businesses; Others (see text field entitled Additional Information on Eligibility for clarification). Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. Confirm the full requirements in the official notice before applying.
Applications for Screening and Functional Validation of Genomic Variants Associated with Human Congenital Anomalies (R01 Clinical Trial Not Allowed) are due January 7, 2028. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Yes — Screening and Functional Validation of Genomic Variants Associated with Human Congenital Anomalies (R01 Clinical Trial Not Allowed) is offered by National Institutes of Health and this listing comes from Grants.gov, an official U.S. federal source. Federal applications generally require registrations (for example SAM.gov or an agency submission portal), so allow extra lead time.
This opportunity targets applicants in Alaska and Hawaii. Check the official notice for exact location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
PAR-27-054 and PAR-27-055 replace COBRE's Phase 1-2-3 model with two tracks: a 15-year Development-Expansion-Sustainability path and a 10-year Expansion-Sustainability path. At $1.5 million per year in direct costs across 23 states and Puerto Rico, with new research cores prohibited in the final phase and eligibility capped at three active awards per institution, the track you claim is the most consequential choice in the application.
Read articleNOT-OD-26-112 released a draft NIH Biosafety Policy for Research Involving Biohazards on August 19, 2026. It would replace the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules, extend IBC jurisdiction from engineered molecules to wild-type agents, toxins and prions, impose 24-hour incident reporting, and make the Biosafety Officer a federally defined role. Here is what actually changes and how to respond before the October 19, 2026 deadline.
Read articleNIH released a draft policy on August 27, 2026 that would require every NIH-supported clinical study to offer participants a plain-language summary of results — clinical trials within one year of completion, all other clinical research by the end of the funding period. It covers observational and behavioral research that ClinicalTrials.gov never touched. Here is the scope, the four requirements nobody has budgeted for, and what to say before the October 26 deadline.
Read article